StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
TRP.BK$4.26+0.00%
Fair $4.26+0.0%

TRP.BK

TRP.BK

Healthcare / Medical Care FacilitiesThailand

$4.26

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $4.26Fund rank 24/100 · Data gapFallback financials|
SA 42/C
F-Score: 2/9
Declining RevenueMargin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-170.3M · quality 43.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 4/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

42/100

C

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years Operating margin has declined for 3 consecutive years
Thesis & Journal · TRP.BKLocal privado en este navegador · TRP.BK
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.4B

P/E

17.0x

↓

EV/EBITDA

9.3x

↓

ROE

5.4%

↑

Gross Margin

50.2%

↑

Debt/Equity

0.00

↓
52-Week Range$4
$4$7

TradingView lightweight chart

TRP.BK price, volumen y niveles de valoración

Último $4.260Periodo -73.0%
Fair value: $4.260

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-17.9%

FCF CAGR

—

FCF margin

-38.1%

FCF / Net income

-2.06x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $471.7M · net income $87.2M · FCF $-179.5M

2022-FY → 2025-FY

Gross margin

50.2%-5.2% pts

Operating margin

23.1%-17.0% pts

Net margin

18.5%-13.2% pts

FCF margin

-38.1%-36.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$471.7M$471.7M$533.7M$707.8M$853.6M
Net Income$87.2M$87.2M$139.4M$192.6M$270.3M
EBITDA$129.4M$129.4M$185.4M$260.9M$355.8M
EPS——0.400.690.77
Gross Margin50.2%50.2%52.7%54.9%55.4%
Operating Margin23.1%23.1%31.8%34.7%40.1%
Net Margin18.5%18.5%26.1%27.2%31.7%
Balance Sheet
Debt/Equity0.000.000.000.010.23
Current Ratio7.917.91———
Cash Flow
Free Cash Flow$-179.5M$-179.5M$-170.3M$104.9M$-13.2M
Returns
ROE5.4%5.4%8.1%11.4%47.5%
Valuation
P/E17.0417.0422.0025.51—
EV/EBITDA9.269.2614.4317.89—
P/B0.870.871.792.91—
Growth & Yield
Revenue Growth-11.6%-11.6%-24.6%-17.1%—
EPS Growth——-42.0%-10.6%—
Dividend Yield5.9%5.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -21.3%

Total return

-21.3%

Start / end P/E

n/dx → n/dx

EPS bridge

0.40 → n/d

Residual

-27.2%

EPS growthn/d
Multiple reratingn/d
Dividend+5.9%
Residual / FX / buybacks / cross-term-27.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.